IVD MEDICAL (01931) subsidiary successfully developed a dual-platform solution for Nipah virus detection and upgraded the group's AI medical strategy.

IVD MEDICAL (01931) Announcement: Recently, there has been an outbreak of Nipah virus in West Bengal, India. The World Health Organization has classified it as a deadly zoonotic virus, with an infection mortality rate of 40% to 75%. Currently, there is no specific treatment or vaccine available. These new emerging infectious disease outbreaks highlight the urgent need for global public health systems to have rapid and accurate diagnostic and alert capabilities. As a high-tech intellectual property capital operation platform that has been deeply involved in the life sciences field for a long time, IVD MEDICAL Holdings Limited ("the Company" or "IVD MEDICAL") has always closely monitored global public health dynamics and continues to provide technical support for the prevention and control of emerging infectious diseases based on its layout in pathogen molecular diagnostics and AI medical ecology. Its subsidiary, Shenzhen Tanhua Biotechnology Co., Ltd. ("Tanhua Biotech"), established through strategic investment by IVD MEDICAL and the biotechnology unicorn company Carbon Cloud Intelligence, focuses on the field of molecular diagnostics, integrating research and development, production, and technical services into a high-tech enterprise dedicated to providing comprehensive molecular diagnostic solutions. Tanhua Biotech's core R&D team has years of experience in in vitro diagnostic reagent development, genomics, bioinformatics, and artificial intelligence. Through efficient collaboration and innovative management, they ensure that their technical solutions are forward-looking and have the ability for rapid transformation. The Company is pleased to announce that Tanhua Biotech has successfully developed a dual-platform testing solution for the Nipah virus, with the capability to provide full-process technical support from rapid screening to accurate tracing. The dual platforms refer to the intelligent fluorescent PCR rapid testing platform and the high-throughput sequencing and intelligent analysis platform. Regarding the intelligent fluorescent PCR rapid testing platform, Tanhua Biotech relies on its independently developed AI primer design platform, which deeply integrates intelligent modules such as genetic retrieval, automated primer design, and multidimensional performance evaluation. The platform, based on machine learning algorithms and a self-built species-specific nucleic acid database, can efficiently identify and lock onto conservative gene regions of high-risk pathogens such as the Nipah virus, enabling rapid and accurate primer design and system optimization. This technology system ensures high specificity and sensitivity, significantly improves amplification uniformity, and suppresses primer dimer formation, thereby enhancing the reliability of the test results. The developed "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR method)" is characterized by its intelligent simplicity, efficient and precise detection, and system stability and compatibility. As for the high-throughput sequencing and intelligent analysis platform, Tanhua Biotech has established a pathogen microbial localization sequencing solution covering the entire process of "wet experiment + dry analysis" based on second-generation sequencing technology. With its self-built and continuously updated multi-species pathogenic genome database (covering 18,628 types of pathogens including bacteria, viruses, fungi, and parasites), the system can achieve synchronous detection and differentiation of the Nipah virus and other coexisting pathogens. It is equipped with a self-developed intelligent microbial data analysis and reporting platform, which integrates one-click biological information analysis, automatic report generation, and visualization functions, enabling a complete end-to-end process from sample receipt to report issuance within 17 hours. This platform not only supports the rapid identification of common, rare, and emerging pathogens but can also be used for virus evolution tracking, transmission chain analysis, and public health risk assessment, providing molecular basis and data insights for precision prevention and control. The rapid deployment of Nipah virus detection capabilities is not only a demonstration of Tanhua Biotech's technological strength but also an important part of IVD MEDICAL's overall AI medical strategy advancement. With the steady implementation of the acquisition of B-Soft Co., Ltd. (stock code: 300451.SZ) (related procedures are proceeding in an orderly manner), the group is accelerating the construction of the next-generation public health prevention and control paradigm of "AI alert + rapid diagnosis + ecological synergy". The rapid response to Nipah virus detection is an important validation of IVD MEDICAL's integrated technological capabilities in emergency public health events. Looking to the future, starting with the mature "AI alert + rapid diagnosis + ecological synergy" capabilities developed in events like this, the group will strive to build an intelligent public health monitoring system that can be quickly replicated and adapted to various scenarios of new infectious diseases and chronic disease management. This product release and strategic statement are another demonstration of IVD MEDICAL's deepening commitment to the core paradigm of "intelligent capital driving continuous profitability from knowledge". Relying on the three curves of K1 (IVD distribution network), K2 (Huajian ecosystem), and K3 (capital operation), the Company will continue to enhance the innovation efficiency and business value of companies within its ecosystem through technology integration, data synergy, and capital empowerment.